Cytochrome P450 in Pharmacogenetics: An Update

Show full item record



Permalink

http://hdl.handle.net/10138/300396

Citation

Tornio , A & Backman , J T 2018 , ' Cytochrome P450 in Pharmacogenetics: An Update ' , Advances in Pharmacology , vol. 83 , pp. 3-32 . https://doi.org/10.1016/bs.apha.2018.04.007

Title: Cytochrome P450 in Pharmacogenetics: An Update
Author: Tornio, A.; Backman, J.T.
Contributor: University of Helsinki, Department of Clinical Pharmacology
University of Helsinki, Department of Clinical Pharmacology
Date: 2018
Language: eng
Number of pages: 30
Belongs to series: Advances in Pharmacology
ISSN: 1054-3589
URI: http://hdl.handle.net/10138/300396
Abstract: Interindividual variability in drug disposition is a major cause of lack of efficacy and adverse effects of drug therapies. The majority of hepatically cleared drugs are metabolized by cytochrome P450 (CYP) enzymes, mainly in families CYP1, CYP2, and CYP3. Genes encoding these enzymes are highly variable with allele distribution showing considerable differences between populations. Genetic variability of especially CYP2C9, CYP2C19, CYP2D6, and CYP3A5 is known to have clear clinical impact on drugs that are metabolized by these enzymes. CYP1A2, CYP2A6, CYP2B6, CYP2C8, and CYP3A4 all show variability that affects pharmacokinetics of drugs as well, but so far the evidence regarding their clinical implications is not as conclusive. In this review, we provide an up-to-date summary of the pharmacogenetics of the major human drug-metabolizing CYP enzymes, focusing on clinically significant examples. © 2018 Elsevier Inc.
Subject: 317 Pharmacy
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
AdvPhTornioBackman_FinalDraft.pdf 436.9Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record